Revelation Biosciences Book Value Per Share Growth & History (REVB)
Revelation Biosciences's book value per share was $5.59 for fiscal 2025.
View full Revelation Biosciences company overviewRevelation Biosciences annual book value per share history
| Fiscal year | Period ended | Book value per share | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $5.59 | -$102.60 | −94.83% |
| 2024 | 2024-12-31 | $108.19 | -$586,593,172.34 | −100.00% |
| 2023 | 2023-12-31 | $586,593,280.54 | -$527,005,256,721.91 | −99.89% |
| 2022 | 2022-12-31 | $527,591,850,002.45 | — | — |
| 2020 | 2020-12-31 | $8,978,649,985,469,667,000.00 | $8,988,224,407,694,138,000.00 | — |
| 2019 | 2019-12-31 | -$9,574,422,224,471,000.00 | — | — |
Revelation Biosciences quarterly book value per share
| Fiscal quarter | Period ended | Book value per share | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $2.58 | -$3,986.16 | −99.94% |
| Q1 2026 | 2026-03-31 | $3.32 | -$4,347,584,683,141,167.00 | −100.00% |
| Q4 2025 | 2025-12-31 | $5.59 | — | — |
| Q3 2025 | 2025-09-30 | $4,908.83 | -$24,159,580,251.92 | −100.00% |
| Q2 2025 | 2025-06-30 | $3,988.73 | -$26,916,538,604.59 | −100.00% |
| Q1 2025 | 2025-03-31 | $4,347,584,683,141,170.50 | $4,347,584,458,121,068.50 | +1932087143.57% |
| Q3 2024 | 2024-09-30 | $24,159,585,160.76 | -$6,035,219,132,699,758.00 | −100.00% |
| Q2 2024 | 2024-06-30 | $26,916,542,593.32 | -$7,812,065,112,757,979.00 | −100.00% |
| Q1 2024 | 2024-03-31 | $225,020,101.84 | -$9,127,941,169,740,524.00 | −100.00% |
| Q3 2023 | 2023-09-30 | $6,035,243,292,284,919.00 | -$447,206,060,046,573,300.00 | −98.67% |
| Q2 2023 | 2023-06-30 | $7,812,092,029,300,572.00 | $592,948,780,681,421,400.00 | — |
| Q1 2023 | 2023-03-31 | $9,127,941,394,760,626.00 | $40,404,186,022,871,000.00 | — |
| Q4 2022 | 2022-12-31 | $6,642,178,849,500,174.00 | $8,162,153,944,760,957.00 | — |
| Q3 2022 | 2022-09-30 | $453,241,303,338,858,240.00 | -$9,165,931,739,027,937,000.00 | −95.29% |
| Q2 2022 | 2022-06-30 | -$585,136,688,652,120,800.00 | -$17,871,174,391,154,518,000.00 | — |
| Q1 2022 | 2022-03-31 | -$31,276,244,628,110,372.00 | -$23,471,138,295,146,033,000.00 | — |
| Q4 2021 · Dec 31 | 2021-12-31 | -$1,519,975,095,260,782.80 | -$8,980,169,960,564,929,000.00 | — |
| Q3 2021 | 2021-09-30 | $9,619,173,042,366,796,000.00 | $9,590,717,771,461,284,000.00 | +33704.54% |
| Q2 2021 | 2021-06-30 | $17,286,037,702,502,398,000.00 | — | — |
| Q1 2021 | 2021-03-31 | $23,439,862,050,517,920,000.00 | — | — |
| Q4 2020 | 2020-12-31 | $8,978,649,985,469,667,000.00 | $8,988,224,407,694,138,000.00 | — |
| Q3 2020 | 2020-09-30 | $28,455,270,905,512,460.00 | — | — |
| Q4 2019 | 2019-12-31 | -$9,574,422,224,471,000.00 | — | — |
Revelation Biosciences book value per share trends
Over the last five fiscal years, Revelation Biosciences's book value per share decreased from $8,978,649,985,469,667,000.00 to $5.59, a change of -$8,978,649,985,469,667,000.00. The latest reported quarter, Q2 2026, shows $2.58.
What book value per share means
Book value per share estimates the common shareholders’ accounting equity represented by each share. It can help compare a company’s balance-sheet value over time, although market value can differ substantially from book value.
How book value per share is calculated
TickerStat calculates book value per share as SEC-reported common shareholders’ equity divided by reported period-end common shares. Preferred equity is subtracted when separately reported, and basic weighted-average shares are used only when period-end shares are unavailable. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Revelation Biosciences source filings ↗